NCT01347671View on ClinicalTrials.gov

Safety and Efficacy of GRT6005 in Pain Due to Diabetic Polyneuropathy

PHASE2CompletedINTERVENTIONAL
Enrollment

189

Participants

Timeline

Start Date

May 31, 2011

Primary Completion Date

January 31, 2012

Study Completion Date

January 31, 2012

Conditions
PainDiabetic Neuropathies
Interventions
DRUG

GRT6005

25µg/day once daily

DRUG

GRT6005

75 µg/day once daily

DRUG

GRT6005

200 µg/day once daily

DRUG

Matching Placebo

Once daily

Trial Locations (22)

1431

Site 4502, Sofia

10117

Site 4101, Berlin

13125

Site 4110, Berlin

19055

Site 4113, Schwerin

20253

Site 4107, Hamburg

22587

Site 4117, Hamburg

23562

Site 4102, Lübeck

24119

Site 4106, Kiel

30159

Site 4108, Hanover

30167

Site 4104, Hanover

32545

Site 4109, Bad Oeynhausen

48145

Site 4105, Münster

55116

Site 4103, Mainz

63739

Site 4112, Aschaffenburg

69120

Site 4115, Heidelberg

88239

Site 4116, Wangen

300594

Site 4406, Timișoara

540139

Site 4401, Târgu Mureş

550166

Site 4407, Sibiu

01307

Site 4111, Dresden

010496

Site 4405, Bucharest

011025

Site 4402, Bucharest

Sponsors

Collaborators (1)

Forest Laboratories
All Listed Sponsors
collaborator

Forest Laboratories

INDUSTRY

lead

Tris Pharma, Inc.

INDUSTRY